摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(1S)-cyclohex-3-en-1-yl]-2,2-dimethylpropan-1-one

中文名称
——
中文别名
——
英文名称
1-[(1S)-cyclohex-3-en-1-yl]-2,2-dimethylpropan-1-one
英文别名
——
1-[(1S)-cyclohex-3-en-1-yl]-2,2-dimethylpropan-1-one化学式
CAS
——
化学式
C11H18O
mdl
——
分子量
166.26
InChiKey
YKRWCJHOVRGRLM-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • PYRROLIDINYL SULFONE RORGAMMA MODULATORS
    申请人:Bristol-Myers Squibb Company
    公开号:US20150191483A1
    公开(公告)日:2015-07-09
    Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
    描述了公式(I)的RORγ调节剂,或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药,其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的,例如,主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
  • PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS
    申请人:Bristol-Myers Squibb Company
    公开号:US20160326108A1
    公开(公告)日:2016-11-10
    Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
  • US9458171B2
    申请人:——
    公开号:US9458171B2
    公开(公告)日:2016-10-04
查看更多